GlassScriptPhysician profile
Nityanand Peri
NPI 1588019749
$10,646.95
in general payments reported to CMS, 2019-2025
59 companies · $26.84 in 2025
The $26.84 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $1,183 · 2021: $2,981 · 2022: $2,287 · 2023: $3,472 · 2024: $111 · 2025: $26.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,213 · Education: $230 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,213.10 |
| Education | $230.07 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,391.98 | 2020-2023 | |
| Janssen Biotech, INC. | $993.41 | 2021-2024 | Darzalex, Imbruvica, Erleada |
| Seagen INC. | $898.44 | 2020-2023 | Adcetris, Padcev |
| Astrazeneca Pharmaceuticals LP | $531.57 | 2021-2023 | Calquence, Lynparza, Tagrisso |
| Celgene Corporation | $496.96 | 2019-2023 | Pomalyst, Reblozyl |
| Eisai INC. | $479.45 | 2020-2023 | |
| Lilly USA, LLC | $447.65 | 2019-2023 | Retevmo, Jaypirca, Verzenio |
| Merck Sharp & Dohme LLC | $346.93 | 2020-2023 | Keytruda, Lynparza |
| Neurocrine Biosciences, INC. | $334.06 | 2021 | |
| Glaxosmithkline, LLC. | $314.20 | 2020-2023 | Jemperli, Zejula, Ojjaara |
| Incyte Corporation | $289.00 | 2019-2023 | Monjuvi, Pemazyre, Jakafi |
| E.R. Squibb & Sons, L.L.C. | $269.92 | 2023 | Pomalyst, Opdivo, Eliquis |
| Pfizer INC. | $268.82 | 2020-2025 | |
| Astellas Pharma US INC | $252.87 | 2022-2023 | Padcev, Xtandi |
| Genentech USA, INC. | $248.31 | 2019-2023 | Perjeta, Phesgo, Kadcyla |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nityanand Peri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.